Actinogen Medical - Cognitive enhancer targeting key diseases
Actinogen Medical is developing its lead asset, small molecule Xanamem, a selective 11β-HSD1 inhibitor designed to cross the blood-brain barrier...
749 Views
Actinogen Medical - Cognitive enhancer targeting key diseases
Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II...
772 Views
Actinogen Medical - Executive interview
Actinogen Medical is an ASX-listed biotech developing its lead asset Xanamem, a specific 11β-HSD1 inhibitor designed to treat cognitive impairment...
851 Views
Actinogen Medical - Well-timed XanaHES study saves the day
Actinogen’s share price has experienced a rather volatile period since May 2019, when it decreased c 70% following the disappointing Phase II...
1.3k Views
Actinogen Releases Phase II Interim Result and Receives US Cornerstone Investment
Actinogen Medical Ltd (ACW AU) announced the results of the Interim Analysis of its Phase II XanADu trial that is conducted independently by the...
260 Views